Reaching toward integrated data approaches for improved drug safety
Too many drugs still cause adverse events after reaching clinical trials, despite all the efforts to eliminate unsafe candidates early. This late-stage attrition remains one of the greatest—and most costly—challenges faced by the pharmaceutical industry.
Researchers are conscious of the potential of big data to streamline preclinical drug development and improve assessments of drug safety, and considerable effort is going into making data infrastructures and research solutions ready to deliver on this promise.
What are the challenges of handling big data? What is the true potential of integrated data and in silico modeling when it comes to safely predicting therapeutic dosing and adverse drug reactions? This white paper looks at the current state of this important field of informatics.